For instance, studies with the FDA-approved CellSearch system demonstrated utility for CTC detection with high levels of CTCs at baseline correlating with poor survival rates19, 20; although heterogeneity in EpCAM expression could limit its applicability in NSCLC patients21. The gene discussed is EPCAM; the disease is non-small cell lung carcinoma.